A Comparison of the Physiological Effects of RSU1069 and RB6145 in the SCCVII Murine Tumour

References

• Adams G. E., Ahmed I., Sheldon P. W., Stratford I. J. Radiation sensitisation and chemopotentiation: RSU1069 a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 1984; 49: 571–8
   PubMed Web of Science ®Google Scholar
• Adams G. E., Ahmed I., Sheldon P. W., Stratford I. J. RSU1069 a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitiser in vitro and in vivo. Int J Radiat Oncol Biol Phys 1984; 10: 1653–6
   PubMed Web of Science ®Google Scholar
• Stratford I. J., O'Neill P., Sheldon P. W., Silver A. R. J., Walling J. M., Adams G. E. RSU1069 a nitroimidazole containing an aziridine group: bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 1986; 35: 105–10
   PubMed Web of Science ®Google Scholar
• Horwich A., Holliday S. B., Deacon J. M., Peckham M. J. A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitiser RSU1069. Br J Radiol 1986; 59: 1238–43
   PubMedGoogle Scholar
• Jenkins T. C., Naylor M. A., O'Neill P., et al. Synthesis and evaluation of α-[[(2-haloethyl)amino]methyl]- 2-nitro-lH-imi-dazole-1-ethanols as prodrugs of α-[(l-aziridinyl)methyl]-2-ni-tro-lH-imidazole-1- ethanol (RSU1069) and its analogues which are radiosensitisers and bioreductively activated cyto-toxins. J Med Chem 1990; 33: 2603–10
   PubMedGoogle Scholar
• Binger M., Workman P. Pharmacokinetic contribution to the improved therapeutic selectivity of a bromoethylamino prodrug (RB6145) of the mixed-function hypoxic cell sensitiser/ cytotoxin α -(1 -aziridinomethyl) -2-nitro-1 H-imidazole-1 -ethanol (RSU1069). Cancer Chemother Pharmacol 1991; 29: 37–47
   PubMedGoogle Scholar
• Cole S., Stratford IJ, Adams G. E., Fielden E. M., Jenkins T. C. Dual function 2-nitroimidazoles as hypoxic radiosensitisers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res 1990; 124: 538–43
   Google Scholar
• Cole S. A., Stratford I. J., Bowler J., et al. Oral (p.o.) dosing with RSU1069 and RB6145 maintains their potency as hypoxic cell radiosensitisers and cytotoxins but reduces systemic toxicity compared with parenteral (i.p.) administration in mice. Int J Radiat Oncol Biol Phys 1991; 21: 387–95
   PubMedGoogle Scholar
• Horsman M. R., Chaplin D. J., Overgaard J. The use of blood flow modifiers to improve the treatment response of solid tumours. Radiother Oncol 1991; (Suppl. 20): 47–52
   Google Scholar
• Chaplin D. J., Peters C. E., Horsman M. R., Trotter MJ. Drug induced perturbations in tumour blood flow: therapeutic potential and possible limitations. Radiother Oncol 1991; (Suppl. 20): 93–101
   Google Scholar
• Chaplin D. J., Horsman M. R. Tumour blood flow changes induced by chemical modifiers of radiation response. Int J Radiat Oncol Biol Phys 1992; 22: 459–62
   PubMedGoogle Scholar
• Durand R. E., LePard N. E. Modulation of tumour hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 1994; 29: 481–6
   PubMedGoogle Scholar
• Hirst D. G., Brown J. M., Hazlehurst JL. Enhancement of CCNU cytotoxicity by misonidazole: Possible therapeutic gain. Br J Cancer 1982; 46: 109–16
   PubMed Web of Science ®Google Scholar
• Shepherd A. P., Riedel G. L., Kiel J. W., Haumshild D., Maxwell L. C. Evaluation of an infrared laser-Doppler blood flowmeter. Am J Physiol 1987; 252, (Gastrointest. Liver Physiol. 15: G832–839).
   Google Scholar
• Kallinowski F., Zander R., Hoeckel M., Vaupel P. Tumour tissue oxygenation as evaluated by computerised-pO2-histog-raphy. Int J Radiat Oncol Biol Phys 1990; 19: 953–61
   PubMed Web of Science ®Google Scholar
• Tamulevicius P., Luscher G., Streffer C. Effects on intermediary metabolism in mouse tissues by Ro-03–8799. Br J Cancer 1987; 56: 315–20
   PubMed Web of Science ®Google Scholar
• Horsman M. R., Christensen K. L., Overgaard J. Hydralazine-in-duced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989; 5: 123–36
   PubMed Web of Science ®Google Scholar
• Horsman M. R., Christensen K. L., Chaplin D. J., Overgaard J. Improved treatment of tumours in vivo by combining the bioreductive drug RSU-1069, hydralazine and hyperthermia. Selective activation of drugs by redox processes. NATO ASI Series, G. E. Adams, A. Breccia, E. M. Fielden, P. Wardman. Plenum Press, New York 1990; 193–202
   Google Scholar
• Vaupel P., Kelleher D. K., Engel T. Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour. Br J Cancer 1994; 69: 46–9
   PubMed Web of Science ®Google Scholar
• Nordsmark M., Grau C., Horsman M. R., Stodkilde Jorgensen H., Overgaard J. The relationship between tumour oxygenation bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995; 34: 329–34
   PubMed Web of Science ®Google Scholar
• Stratford I. J., Walling J. M., Silver A. R. J. The differential cytotoxicity of RSU1069: cell survival studies indicating interaction with DNA as a possible mode of action. Br J Cancer 1986; 53: 339–44
   PubMed Web of Science ®Google Scholar
• Horsman M. R., Kristjansen P. E. G., Mizuno M., et al. Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF mice. Int J Radiat Oncol Biol Phys 1992; 22: 451–4
   PubMedGoogle Scholar
• Stone H. B., Minchinton Al, Lemmon M., Menke D., Brown J. M. Pharmacological manipulation of tumour blood flow: Lack of correlation between alteration of mean arterial blood pressure and changes in tumour perfusion. Int J Radiat Oncol Biol Phys 1991; 22: 79–86
   Google Scholar
• Streffer C., Zolzer F., Tamulevicius P. Studies on combined treatment with X-rays, hyperthermia and hypoxic cell sensitis-ers on tumours. Radiation research: A twentieth-century perspective, vol. 2, congress proceedings, W. C. Dewey, M. Edington, R. J. M. Fry, E. J. Hall, G. F. Whitmore. Academic Press, San Diego 1992; 1021–26
   Google Scholar
• Nishimura Y., Hiraoka M., Jo S., et al. Microangiographic and histological analysis of the effects of hyperthermia on murine tumour vasculature. Int J Radiat Oncol Biol Phys 1988; 15: 411–420
   PubMed Web of Science ®Google Scholar
• Bleehen N. M., Honess D. J., Morgan J. E. Interaction of hyperthermia and the hypoxic cell sensitiser Ro-07–0582 on the EMT6 mouse tumour. Br J Cancer 1977; 35: 299–306
   PubMed Web of Science ®Google Scholar
• George K. G., Hirst D. G., McNally N. J. Effect of hyperthermia on cytotoxicity of the radiosensitiser Ro-07–0582 in a solid mouse tumour. Br J Cancer 1977; 35: 372–5
   PubMedGoogle Scholar
• Lehman C. M., Stewart J. R. In vivo cytotoxicity of misonidazole and hyperthermia in a transplanted mouse mammary tumour. Radiat Res 1983; 96: 628–34
   PubMedGoogle Scholar
• Stratford I. J. Hyperthermia and hypoxic cell radiosensitisers in combination. Hyperthermia and cancer treatment, vol. 1, L. J. Anghiteri, J. Robert. CRC Press Inc, Florida 1986; 151–68
   Google Scholar
• Teicher B. A., Herman T. S., Holden S. A. Effect of pH oxygenation and temperature on the cytotoxicity and radiosensitisa-tion by etanidazole. Int J Radiat Oncol Biol Phys 1991; 20: 723–31
   PubMedGoogle Scholar
• Chaplin D. J., Acker B. The effect of hydralazine on the tumour cytotoxicity of the hypoxic cell cytotoxin RSU-1069: Evidence for therapeutic gain. Int J Radiat Oncol Biol Phys 1987; 13: 579–85
   PubMed Web of Science ®Google Scholar
• Bremner J. C. M., Stratford I. J., Bowler J., Adams G. E. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 1990; 61: 717–21
   PubMed Web of Science ®Google Scholar
• Edwards H. E., Bremner J. C. M., Stratford I. J. Induction of tumour hypoxia by FAA and TNF. Int J Radiat Biol 1991; 60: 373–7
   PubMed Web of Science ®Google Scholar
• Wood P. J., Sansom J. M., Stratford I. J., et al. Induction of hypoxia in experimental murine tumours by the nitric oxide synthase inhibitor NG-nitro-L-arginine. Cancer Res 1994; 54: 6458–63
   PubMed Web of Science ®Google Scholar